Articles By Shivani Garg, MD, PhD

HCQ target dosing using bullseye imagery

Hydroxychloroquine: 5 mg/kg/day Is Only the Starting Point

By Shivani Garg, MD, PhD  Donald Thomas, MD

Hydroxychloroquine (HCQ) is one of the most important drugs in rheumatology, especially for systemic lupus erythematosus (SLE). It reduces flares, organ damage, cardiovascular events, and pregnancy complications, and it improves survival.

Read Article
HCQ target dosing using bullseye imagery

Hidroxicloroquina: 5 mg/kg/día es solo el punto de partida

By Shivani Garg, MD, PhD  Donald Thomas, MD

La hidroxicloroquina (HCQ) es un fármaco fundamental para el lupus, pero la dosificación basada en el peso es un predictor poco fiable de la exposición al fármaco. La monitorización de los niveles de HCQ en sangre total es una estrategia superior para optimizar la eficacia y la seguridad, permitiendo a los médicos identificar a los pacientes infradosificados, sobredosificados o con falta de adherencia.

Read Article
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Profile picture for user Shivani Garg, MD, PhD
  • Shivani Garg, MD, PhD

  • Dr. Shivani Garg is an Associate Professor in the Section of Rheumatology at the Yale School of Medicine, where she serves as Director of the Yale Lupus Clinical Research Program and co‑Director of the Yale Lupus Program. Her research aims to transform lupus care through precise and personalized approaches that address gaps in cardiovascular risk management, optimize therapeutic drug monitoring, and support shared decision‑making for patients with lupus and lupus nephritis.

×